USA has detected at least 15 confirmed cases of clots, including cerebral thrombosis, in women who have been administered the vaccine against coronavirus de Janssen, branch belga de Johnson & Johnson (J&J).
This was announced at a meeting of the Advisory Committee on Immunization Practices (ACIP), a body made up of 15 independent scientists that is evaluating the data on this serum before issuing a recommendation that will serve as a guide for the US authorities. on what to do with that vaccine from now on.
- US: California Universities to Require Coronavirus Vaccine for Students and Staff
- US: Coronavirus hospitalizations drop among elderly
- The United States registers 786 deaths and 56,236 infections from coronavirus in one day
USA advised on April 13 to suspend the administration of the J&J vaccine after six cases of cerebral thrombosis were initially detected in women under 48 years of age, of which one died.
During the ACIP session, Dr. Tom Shimabukuro, head of vaccine safety at the Centers for Disease Control and Prevention (CDC), updated that data, noting that there are three deaths so far, and seven are still hospitalized, of which four are in intensive care units.
Of the 15 patients, 13 are between 18 and 49 years old, and 12 of them developed cerebral thrombosis, although many had clots in other parts of the body.
The initial symptom was headache, which usually began six days after being vaccinated, although, as time passed, the patients developed nausea, vomiting, abdominal pain, weakness on one side of the body, difficulties speaking, loss of consciousness and spasms, detailed the doctor.
Shimabukuro noted that seven of the women were obese, two had hypothyroidism, two had high blood pressure, and two were taking contraceptives.
It is not clear at this time if any of these factors could contribute to increasing the risk of developing thrombi.
By now, 8 million doses of J&J have been injected into USA, whose administration has practically been paused in the country after the recommendation of last day 13.
Shimabukuro said there could be potential cases in men and they are currently being studied.
Specifically, the scientist mentioned a 25-year-old patient who developed a clot when he participated in clinical trials of the vaccine.
Representatives of J&J participate in today’s meeting, who assured that these cases are being taken “very seriously.” The company supports putting a label on the vaccine warning of potential risks.
ACIP is comprised of 15 independent experts and plans to review the vaccine data until 5:00 p.m. EST USA of this friday.
At the end of the session it is expected that a recommendation will be voted on what to do from now on with the J&J serum.
If ACIP advises any changes to the vaccine’s label, such as a warning about potential risks or a recommendation that it be administered only to certain population groups, CDC Director Rochelle Walensky should sign it later, before the FDA will be in charge of making any changes to the labeling.
IT MAY INTEREST YOU
- They arrest 30 soldiers accused of forced disappearance in Mexico
- Colombia: Relatives break into hospital and “steal” body of a patient killed by coronavirus | VIDEO
- “Poverty in Ecuador has increased alarmingly”: 4 urgent challenges that Guillermo Lasso must face
- Japan decides to dump processed water from the Fukushima nuclear power plant into the Pacific
- The shocking moment when a drug dealer kills a policeman at a traffic control